This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
RxSight Launches New Light Adjustable Lens Product MT
RxSight, Inc. Announces Commercial Launch of its Newest Light Adjustable Lens??, the LAL+??, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting CI
Rxsight Insider Sold Shares Worth $997,946, According to a Recent SEC Filing MT
Needham Raises Price Target on RxSight to $64 From $53, Maintains Buy Rating MT
Oppenheimer Adjusts RxSight Price Target to $61 From $54, Maintains Outperform Rating MT
RxSight's Q4 Adjusted Loss Narrows, Sales Increase; Reiterates 2024 Revenue Guidance MT
Transcript : RxSight, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (RXST) RXSIGHT Reports Q4 Revenue $28.6M, vs. Street Est of $27.9M MT
Rxsight, Inc. Reiterates Earnings Guidance for the Full Year 2024 CI
RxSight, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
RxSight, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Rxsight Insider Sold Shares Worth $1,350,000, According to a Recent SEC Filing MT
Rxsight Insider Bought Shares Worth $406,673, According to a Recent SEC Filing MT
RxSight Insider Sold Shares Worth $525,939, According to a Recent SEC Filing MT
Stifel Adjusts Price Target on RxSight to $54 From $45, Maintains Buy Rating MT
Rxsight Insider Sold Shares Worth $1,182,660, According to a Recent SEC Filing MT
Rxsight Insider Sold Shares Worth $500,004, According to a Recent SEC Filing MT
Rxsight Insider Sold Shares Worth $351,411, According to a Recent SEC Filing MT
Rxsight Insider Sold Shares Worth $1,403,120, According to a Recent SEC Filing MT
Rxsight Insider Sold Shares Worth $1,496,706, According to a Recent SEC Filing MT
Oppenheimer Raises RxSight Price Target to $54 From $50, Maintains Outperform Rating MT
RxSight Insider Sold Shares Worth $480,006, According to a Recent SEC Filing MT
Rxsight Insider Sold Shares Worth $292,555, According to a Recent SEC Filing MT
Oppenheimer Raises RxSight Price Target to $50 From $46, Maintains Outperform Rating MT
Transcript : RxSight, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:00 PM
Chart RxSight, Inc.
More charts
RxSight, Inc. is a commercial-stage medical technology company, which is engaged in improving the vision of patients following cataract surgery. The Company’s RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. It designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patient’s vision outcomes.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
51.75 USD
Average target price
62.62 USD
Spread / Average Target
+21.01%
Consensus
  1. Stock Market
  2. Equities
  3. RXST Stock
  4. News RxSight, Inc.
  5. Needham Starts RxSight at Buy With $18 Price Target